BJMO - volume 17, issue 4, june 2023
E. van Gogh MD, L. Baisier MD, P. Reyntiens MD, J. Liu MD, M. Rasschaert MD, PhD
Immunotherapy has revolutionised cancer therapy for specific tumour types. The dismal prognosis of melanoma patients with advanced stage has improved but remains poor. With the increasing use of these monoclonal antibodies, toxicities are becoming more prevalent. Neurological adverse events are still rare but have an enormous impact on the continuum of care. This study reports a case of a 70-year-old man with stage IIIc melanoma who presented with cerebral vasculitis after rechallenge therapy with ipilimumab/nivolumab.
(Belg J Med Oncol 2023;17(4):128–31)
Read moreBJMO - volume 14, issue 1, january 2020
P. Specenier MD, PhD, E. van Gogh MD
(BELG J MED ONCOL 2020;14(1):8–12)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
